Compare Lowe`s Companies Inc (LOW) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Sanofi SA — how do they compare? Lowe`s Companies Inc trades at $202.73 (market cap $114.78B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Lowe`s Companies Inc and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| LOW | SNY | |
|---|---|---|
Market Cap | $114.78B | $104.83B |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $52.34 |
52-Week Low | $204.76 | $41.33 |
Enterprise Value | $156.54B | $121.32B |
Dividend Yield | 2.44% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $204.08, down 2.23% on the day, amid a bearish technical signal. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $3.03 exceeding the $2.97 estimate. Revenue for 2025 was $83.67 billion, with a net income margin of 7.51%. The company maintains a strong dividend history, recently declaring a $1.25 per share dividend payable in August 2026.
The outlook is mixed. Strong analyst consensus, with a $260.88 price target and 60.79% buy ratings, suggests upside potential. However, high debt levels, with a debt-to-asset ratio of 82.33% for 2025, and a projected net cash flow deficit of $2.3 billion for 2026 present significant financial risks. Competitive pressures in the home improvement sector remain a key challenge.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
